Breakthroughs in these areas may be attributed to the maturation of liver-targeted delivery systems (e.g., GalNAc coupling technology), which have made metabolic disorders (e.g., PCSK9 targeting) more amenable to efficient gene silencing. The gene discussed is PCSK9; the disease is metabolic disease.